| Identification | Back Directory | [Name]
NECA | [CAS]
35920-39-9 | [Synonyms]
NECA
744-96
765-21
D-NECA
B-744-96
5'-ETHYLCARBOXAMIDOADENOSINE
Adenosine-5'-ethylcarboxamide
5'-N-Ethylcarboxamideadenosine
5'-N6-Ethylcarboxamidoadenosine
N-ethyl-5'-carboxamidoadenosine
5'-Ethylcarboxamido-D-adenosine
adenosine-5’-(n-ethylcarboxamide
Adenosine Receptor Agonist, NECA
5'-(N-ETHYLCARBOXAMIDO)-ADENOSINE
NECA,5′-(N-Ethylcarboxamido)adenosine
5’-n-ethylcarboxamidoadenosinehemihydrate
adenosine-5’-(n-ethyl)carboxamidehemihydrate
5’-n(sup6)-ethylcarboxamidoadenosinehemihydrate
1-(6-Amino-9H-purin-9-yl)-1-deoxy-N-ethyl-β-D-ribofuranuronamide
b-D-RibofuranuronaMide, 1-(6-aMino-9H-purin-9-yl)-1-deoxy-N-ethyl-
1-(6-Amino-(9H)-purin-9-yl)-1-deoxy-N-ethyl-b-D-ribofuranuronamide
1-(6-AMINO-9H-PURIN-9-YL)-1-DEOXY-N-ETHYL-BETA-D-RIBOFURANURONAMIDE
NECA, 1-(6-Amino-9H-purin-9-yl)-1-deoxy-N-ethyl-D-ribofuranuronamide
1-(6-amino-9h-purin-9-yl)-1-deoxy-n-ethylribofuranuronamidehemihydrate
1-(6-amino-9h-purin-9-yl)-1-deoxy-n-ethyl-ribofuranuronamidhemihydrate | [Molecular Formula]
C12H16N6O4 | [MDL Number]
MFCD00069195 | [MOL File]
35920-39-9.mol | [Molecular Weight]
308.29 |
| Chemical Properties | Back Directory | [Appearance]
White Solid | [Melting point ]
229-231°C | [density ]
1.87±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C
| [solubility ]
45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.2 mg/mL Solutions may be stored for several days at 4?#x00b0;C.
| [form ]
powder
| [pka]
12.93±0.70(Predicted) | [color ]
white
| [Stability:]
Hygroscopic | [InChIKey]
JADDQZYHOWSFJD-FLNNQWSLSA-N | [CAS DataBase Reference]
35920-39-9 |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
A potent adenosine receptor agonist. Inhibits platelet aggregation and is centrally active in vivo | [Definition]
ChEBI: A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group. | [Biological Activity]
Potent adenosine receptor agonist (K i values are 14, 20 and 6.2 nM for human A 1 , A 2A and A 3 receptors respectively; EC 50 = 2.4 μ M for human A 2B ). Inhibits platelet aggregation and is centrally active in vivo . | [General Description]
A cell-permeable adenosine analog that acts a potent non-selective agonist of adenosine receptors (Ki = 14 nM, 20 nM, 2.4 μM and 6.2 nM for A1, A2A, A2B, A3, respectively). Increases intracellular cAMP production (EC50 = 3.1 μM in A2B expressing CHO cells). Shown to increase glucagon release in a dose-dependent manner and inhibit insulin release at low concentrations. Although at higher concentration some insulin release is observed. Also, displays a wide range adenosine-dependent effects, such as blocking platelet aggregation and inhibiting DNA synthesis. When administered at reperfusion, it is shown reduce infarction and block the formation of the mitochondrial permeability transition pore by activating p70S6 kinase. | [Biochem/physiol Actions]
Reversible: yes | [storage]
Store at -20°C |
| Safety Data | Back Directory | [Hazard Codes ]
T+ | [Risk Statements ]
28 | [Safety Statements ]
22-26-36-45 | [RIDADR ]
UN 2811 6.1/PG 2
| [WGK Germany ]
3
| [RTECS ]
VJ2232000
| [HazardClass ]
6.1(a) | [PackingGroup ]
I | [HS Code ]
29349990 |
|
|